Using 920 sera, we compared the specificity and reproducibility of the hemagglutination treponemal test for syphilis with those of the fluorescent treponemal antibody-absorption test and the microhemagglutination assay for Treponema pallidum antibodies; we found all three tests to be comparable. However, the hemagglutination treponemal test for syphilis, like the microhemagglutination assay for T. pallidum antibodies, lacked sensitivity in sera from patients with primary syphilis.
In a previous study (3) , our laboratory evaluated two commercially available treponemal antibody kits for diagnosing syphilis. One kit, which used turkey erythrocytes as the carrier for the Treponema pallidum antigen (6) , was found to be less sensitive in sera from patients with all stages of syphilis than the fluorescent treponemal antibody-absorption (FTA-ABS) test. The other hemagglutination test, the microhemagglutination assay for T. pallidum antibodies (MHA-TP) (1, 5) , although slightly less sensitive in sera from patients with early primary syphilis (2, 3) , was as sensitive as the FTA-ABS test in sera from patients with other stages of syphilis and was as specific as the FTA-ABS test in sera from nonsyphilitics.
In 1978, the hemagglutination treponemal test for syphilis (HATTS) was described (9) . T. pallidum antigen, coupled with turkey erythrocytes, is also used as the antigen in this hemagglutination test. The initial evaluation (9) and one additional evaluation (4) indicated that the HATTS was comparable to the MHA-TP.
In the present study, the sensitivity, specificity, and reproducibility of the HATTS were compared with those of the MHA-TP, the FTA-ABS test, and the Venereal Disease Research Laboratory (VDRL) slide test, a nontreponemal test.
MATERIALS AND ETHODS Sera. For the evaluation of the HATTS, two groups of sera were used. One group consisted of 439 frozen sera from the Venereal Disease Serology Laboratory Serum Bank, Centers for Disease Control, Atlanta, Ga., and the other group consisted of 481 fresh sera from the DeKalb County, Ga., Sexually Transmitted Diseases Clinic. Most of the syphilitic sera from the sexually transmitted diseases clinic were from patients who were treated either the week before or on the day their sera were drawn. Therefore, no attempt was made to separate these sera into treated or untreated categories.
To assess the reproducibility of the HATTS, we dispensed each of six sera into 10 portions and coded them so that they would be included with the routine testing of the frozen sera over 5 consecutive testing days and with five periodic testings throughout the study. These six sera were selected so that two were reactive at a 3 to 4+ level in the FTA-ABS test, but reactive only at a 1 to 2+ level in the MHA-TP (both from patients with primary syphilis), two RESULTS A total of 920 sera were tested in the study. Tables 1 and 2 show the test results for the 592 nonsyphilitic sera. Twelve of these sera were known to be from patients with diseases other than syphilis, including leprosy, lupus, and malaria. Of these 12 sera, 2 were reactive in the FTA-ABS test only and 1 was weakly reactive in the VDRL test. The possible causes of the other false-positive reactions are unknown. Of the 22 sera which were false-positive in the FTA-ABS test, 13 were read as 1+, 6 as 2+, and 3 as 3+. Of the 11 sera which were false-positive in the HATTS, 7 reacted at a 1+ level, 2 at 2+, and 2 at 3+. Both of the sera which were falsepositive in the MHA-TP were reactive at a 1+ level. For all sera, fresh or frozen, which gave unequivocal results, there were no statistically significant differences in specificities among the results of the HATTS, MHA-TP, FTA-ABS, and VDRL tests. However, if sera which reacted in more than one test were excluded from the calculations, then there were significant differences, in fresh sera only, between the results of the FTA-ABS test and those of the HATTS (P < 0.001) or the VDRL test (P < 0.01). There was a significant difference between the results of the MHA-TP and those of the VDRL test (P < 0.03), but there were no signiflcant differences between HATTS results and those of the MHA-TP or the VDRL test. The significant difference between the FTA-ABS test results for frozen sera and the FTA-ABS test results for fresh sera (P < 0.02) is of interest. Among the other three tests, no significant differences in specificity existed between the results for fresh sera and those for frozen sera.
The results of tests on the 328 syphilitic sera are shown in Table 3 . Of the primary syphilitic sera which were nonreactive in the treponemal tests, at least 50% were from dark-field-positive chancres. Of the 79 primary syphilitic sera, 2 were nonreactive in the FTA-ABS test only, 2 were nonreactive in the HATTS only, 8 were nonreactive in both the HATTS and the MHA-TP, and 1 was nonreactive in the MHA-TP only. All sera from patients with secondary syphilis were reactive in all treponemal tests. Those nonreactive in the VDRL test were from patients with treated secondary syphilis. In the latent category, one serum was nonreactive in the MHA-TP only, and one serum was nonreactive in the FTA-ABS test only. In addition to these nonreactive sera, two sera from patients categorized as having late cardiovascular syphilis were nonreactive in both hemagglutination tests. Since treatment affects the reactivity of the VDRL test, this test was not included in the calculations for sensitivity. The only signiflcant differences in sensitivity existed between the b Sensitivities of the HATTS, MHA-TP, FTA-ABS, and VDRL tests in sera from patients with secondary syphilis were 100, 100, 100, and 88.8%, respectively.
'Sensitivities of the HATTS, MHA-TP, FTA-ABS, and VDRL tests in sera from patients with latent syphilis were 100, 99, 99, and 95.2%, respectively.
d Sensitivities of the HATTS, MHA-TP, FTA-ABS, and VDRL tests in sera from patients with cardiovascular syphilis were 89.5, 89.5, 100, and 38.1%, respectively.
'Sensitivities of the HATTS, MHA-TP, FTA-ABS, and VDRL tests in sera from patients with neurosyphilis were 100, 100, 100, and 90%, respectively.
f Sensitivities of the HATTS, MHA-TP, FTA-ABS, and VDRL tests in sera from patients with past syphilis were 100, 100, 100, and 48%, respectively. results of the FTA-ABS test and those of the MHA-TP (P < 0.04) and HATTS (P < 0.02) with sera from patients with the primary stage of syphilis. There was no significant difference between sensitivities of the HATTS and the MHA-TP in sera from patients with this stage of syphilis. Of the 920 sera tested, there were only 2 reactions with nonsensitized control cells in the HATTS and 5 in the MHA-TP. Such reactions, of course, invalidate the test unless the sera can be diluted or absorbed to eliminate the reactions.
Each of six sera were tested 10 times; reproducibility, as shown in Table 4 , was approximately the same for the HATTS, the FTA-ABS test, and the VDRL test. Only the MHA-TP was 100% repeatable. A gray area ofreading occurred in all three tests, which we designated as N-+ and +-1 for the two hemagglutination tests. These sera were retested before a final reading was recorded. Table 5 shows the results of the retesting of these sera and sera which were initially either nonreactive or reactive at a 1+ level. In the MHA-TP, all questionable sera were read on repeat testing as nonreactive, whereas 88% of the 22 sera falling in the gray area on the first reading were reported as nonreactive upon repeat testing in the HATTS. These nonreactive results agreed with the clinical diagnoses.
On each ofthe 27 testing days, reactive control sera were quantitated for both the MHA-TP and the HATTS. For the MHA-TP, the endpoint titer was 1:5,120 for 19 days, 1:2,560 for 4 days, and 1:10,240 for 4 days. For the HATTS with the control sera used for the first 21 days of the study, the endpoint titer was 1:5,120 for 14 days and 1:2,560 for 7 days. For the last 6 Reproducibility of the HATTS is comparable to those of the FTA-ABS and VDRL tests. The HATTS appears to be less reproducible than the MHA-TP. However, this may reflect our choice of an untreated primary serum for testing reproducibility or our unfamiliarity with the test rather than the reproducibility of the test itself. We suggest that all sera falling in the N-±-±-1 range be retested before the final report is made.
The HATTS kit is no more complicated to use than the MHA-TP kit and has the advantage of a 1-h incubation period, as opposed to the 4-h incubation period required for the MHA-TP. In our study, we did not attempt to evaluate the stability of the reconstituted hemagglutination reagents, but we suggest that the reconstituted cells in both the MHA-TP and the HATTS be used within 3 days.
During the testing period, five HATTS kits showed unexpected autoagglutination, three times with the sensitized cells and twice with the unsensitized cells. We could not determine the source of this autoagglutination, but apparently, we eliminated the problem empirically by using all disposable laboratory ware for preparing and dispensing the cells and sera.
On the basis of our data and the experience of Wentworth et al. (9) and Peter et al. (4), we concluded that the HATTS appears to be as valuable as the MHA-TP as a test for confirming syphilis. However, the FTA-ABS test is still necessary for those sera with unsensitized control-cell reactions and may be preferred for confirming primary syphilis and late cardiovascular syphilis.
